SLC5A2 and hydrops fetalis: Furthermore, considering that patients with a long history of AMI are more likely to have shared indications for SGLT2 inhibitors (e.g., T2DM or HF), it may be hasty to determine that the benefit of SGLT2 inhibitors for patients is in the context of AMI.